Tumors: Binaschi (Menarini), 'elacestrant blocks metastatic breast cancer growth'

"Elacestrant is an oral molecule that binds to the estrogen receptor, which in metastatic breast cancer is the fuel that makes the tumor cell grow, and destroys it. Elacestrant has become the global reference, an effective molecule, but also extremely tolerated in breast cancer". This was stated by Monica Binaschi, director of the Department of Preclinical and Translational Sciences at Menarini Ricerche, at the press conference promoted in Milan by Menarini Stemline Italia to present the new perspectives in the treatment of hormone-sensitive metastatic breast cancer with elacestrant, the reimbursement of which has been approved by the Italian Medicines Agency (AIFA) for patients with Esr1 mutations who have already received first-line endocrine therapy in association with Cdk4/6 inhibitors.

"We invest in research because we believe that studying the molecular mechanisms underlying cancer can really make a difference," Binaschi highlights. "Our commitment goes beyond metastatic cancer," he underlines. "We are involved in multiple clinical studies. One of these is Elegant, a phase III study, involving 40 Italian clinical centers, which aims to explore the activity of elacestrant in patients with early cancer. A very important aspect for determining subsequent therapy. We are the second country, after the United States, recruiting patients for this clinical study. A source of national pride," he concludes.